Author:
Boccardo F.,Verri E.,Guglielmini P.
Reference87 articles.
1. No authors (1995). Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists’ Collaborative Group. Lancet, 346, 265–269.
2. No authors (2000). Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists’ Collaborative Group. Lancet, 355, 1491–1498.
3. Akaza H., Homma Y., Okada K., Yokoyama M., Usami M., Hirao Y., Tsushima T., Ohashi Y. and Aso Y. (2003). A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: results of the 5-year follow-up. BJU Int, 91, 33–36.
4. Alberts S.R. and Blute M.L. (2001). Chemoprevention for prostatic carcinoma: the role of flutamide in patients with prostatic intraepithelial neoplasia. Urology, 57, 188–190.
5. Asbury R.F., Brunetto V.L., Lee R.B., Reid G. and Rocereto T.F. (2002). Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Am J Clin Oncol, 25, 557–560.